NEO2734 (EP31670) is an orally active dual p300/CBP and BET bromodomain selective inhibitor, with IC 50 values of <30 nM for both p300/CBP and BET bromodomains. NEO2734 is active in SPOP mutant and wild-type prostate cancer.
性状
Solid
体外研究(In Vitro)
NEO2734 (1 μM) induces differentiation and G1-phase cell cycle arrest.NEO2734 (1 μM) rapidly induces squamous differentiation in NMC cell lines, and expression of the terminal squamous differentiation marker, involucrin, or keratins.NEO2734 is active in both hotspot mutant (F133V) and non-hotspot mutant (Q165P) PCa cells in vitro and in vivo. has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究(In Vivo)
NEO2734 (5, 8, 10 mg/kg, orally) inhibits growth and prolongs survival in pre-clinical xenograft models. has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Model: Mice (PER-403 and 14169 mo
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years;4°C 2 years
ClinicalTrial
参考文献
[1]. Chevaun D Morrison-Smit, et al. Combined Targeting of the BRD4-NUT-p300 Axis in NUT Midline Carcinoma by Dual Selective Bromodomain Inhibitor, NEO2734. Mol Cancer Ther. 2020 Jul;19(7):1406-1414.[2]. Yuqian Yan, et al. The novel BET-CBP/p300 dual inhibitor NEO2734 is active in SPOP mutant and wild-type prostate cancer. EMBO Mol Med. 2019 Nov 7;11(11):e10659.
溶解度数据
In Vitro: DMSO : 100 mg/mL (229.65 mM; Need ultrasonic)配制储备液